{"DataElement":{"publicId":"2777660","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention Type","preferredDefinition":"A description of graft versus host disease prophylaxis.","longName":"GVHD_PRV_INT_TYP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2775614","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention Type","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._Therapeutic, nutritional, environmental, social and or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._Something distinguishable as an identifiable class based on common qualities.","longName":"GVHD_PRV_INT_TYP","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2681981","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.:An attempt to prevent disease.","longName":"C3063:C15843","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graft Versus Host Disease","conceptCode":"C3063","definition":"A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A1889B5-158A-2594-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-14","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-14","modifiedBy":"ONEDATA","dateModified":"2007-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223243","version":"1","preferredName":"Type","preferredDefinition":"A subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F629F5E5-DE63-1DFD-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"54F9D5EC-F56A-5F4E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2775669","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention Type","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._Therapeutic, nutritional, environmental, social and or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._Type; a subdivision of a particular kind of thing.","longName":"GVHD_PRV_INT_TYP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Sirolimus (Rapamycin, Rapamune)","valueDescription":"Sirolimus","ValueMeaning":{"publicId":"2760061","version":"1","preferredName":"Sirolimus","longName":"2760061","preferredDefinition":"A drug used to help prevent rejection of organ and bone marrow transplants by the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sirolimus","conceptCode":"C1212","definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FE455C3-3ABF-5319-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-06-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54FB5BE0-0172-7379-E044-0003BA3F9857","beginDate":"2008-08-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"ALEYR","dateModified":"2008-08-21","deletedIndicator":"No"},{"value":"FK 506 (Tacrolimus, Prograf)","valueDescription":"Tacrolimus (Prograf, Protopic Ointment, Advagraf)","ValueMeaning":{"publicId":"2775673","version":"1","preferredName":"Tacrolimus (Prograf, Protopic Ointment, Advagraf)","longName":"2775673","preferredDefinition":"A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tacrolimus","conceptCode":"C1311","definition":"A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FB5BE0-01E0-7379-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54FB5BE0-01F9-7379-E044-0003BA3F9857","beginDate":"2008-08-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"ALEYR","dateModified":"2008-08-21","deletedIndicator":"No"},{"value":"ALG, ALS, ATG, ATS","valueDescription":"Antithymocyte Globulin And/Or Antilymphocyte Serum","ValueMeaning":{"publicId":"2775675","version":"1","preferredName":"Antithymocyte Globulin And/Or Antilymphocyte Serum","longName":"2775675","preferredDefinition":"A purified gamma immunoglobulin with immunosuppressive properties.  Obtained from rabbits that have been immunized with human thymocytes, antithymocyte globulin specifically recognizes and destroys T lymphocytes.  Although the exact mechanism of action is not completely understood, it appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering antithymocyte globulin with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host disease. (NCI04): Used to indicate that either or both of two items or options: Immunoglobulins raised xenogeneically against lymphocyte populations.  It is used both as a test for histocompatibility and in conjunction with other immunosuppressive agents to suppress rejection of grafts or organ transplants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antilymphocyte Serum","conceptCode":"C62577","definition":"Immunoglobulins raised xenogeneically against lymphocyte populations.  It is used both as a test for histocompatibility and in conjunction with other immunosuppressive agents to suppress rejection of grafts or organ transplants.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FB5BE0-0246-7379-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54FB5BE0-025F-7379-E044-0003BA3F9857","beginDate":"2008-08-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"ALEYR","dateModified":"2008-08-21","deletedIndicator":"No"},{"value":"Corticosteriods (systemic)","valueDescription":"Corticosteroid","ValueMeaning":{"publicId":"3951357","version":"1","preferredName":"Corticosteroid","longName":"3951357","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAE91AA1-BCFE-7D56-E040-BB89AD4361DC","latestVersionIndicator":"Yes","beginDate":"2013-11-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAE91AA1-BD16-7D56-E040-BB89AD4361DC","beginDate":"2008-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"ONEDATA","dateModified":"2013-11-11","deletedIndicator":"No"},{"value":"Methotrexate (MTX) (Amethopterin)","valueDescription":"Methotrexate","ValueMeaning":{"publicId":"3233637","version":"1","preferredName":"Methotrexate","longName":"3233637","preferredDefinition":"An antimetabolite with antineoplastic and immunomodulating properties.  Methotrxate inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A27C18C9-DC55-820E-E040-BB89AD432300","latestVersionIndicator":"Yes","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAE91AA1-BD52-7D56-E040-BB89AD4361DC","beginDate":"2008-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"ONEDATA","dateModified":"2013-11-11","deletedIndicator":"No"},{"value":"Other agent","valueDescription":"Other Pharmacologic Substance","ValueMeaning":{"publicId":"2775670","version":"1","preferredName":"Other Pharmacologic Substance","longName":"2775670","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FB5BE0-0144-7379-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"MAESKEB","dateModified":"2018-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAE91AA1-BD70-7D56-E040-BB89AD4361DC","beginDate":"2008-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"ONEDATA","dateModified":"2013-11-11","deletedIndicator":"No"},{"value":"Blinded randomized trial","valueDescription":"Blinded Randomized Clinical Trial","ValueMeaning":{"publicId":"3951358","version":"1","preferredName":"Blinded Randomized Clinical Trial","longName":"3951358","preferredDefinition":"Describes an experiment or clinical trial in which patients (single-blinded) or the patients and their doctors (double-blinded) do not know which drug or treatment is being given.: A study in which the participants are assigned by chance to separate groups that compare different treatments; neither the researchers nor the participants can choose which group.  Using chance to assign people to groups means that the groups will be similar and that the treatments they receive can be compared objectively.  At the time of the trial, it is not known which treatment is best. It is the patient's choice to be in a randomized trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinded","conceptCode":"C49068","definition":"A characteristic of experiment design in which one or more groups involved (receiving, administering, or evaluating intervention) are unaware of which intervention any particular subject is receiving.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Randomized Clinical Trial","conceptCode":"C15417","definition":"Assignment of subjects by chance to groups that receive different treatments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAE91AA1-BD80-7D56-E040-BB89AD4361DC","latestVersionIndicator":"Yes","beginDate":"2013-11-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAE91AA1-BD99-7D56-E040-BB89AD4361DC","beginDate":"2013-11-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"ONEDATA","dateModified":"2013-11-11","deletedIndicator":"No"},{"value":"In vivo immunotoxin","valueDescription":"in vivo Immunotoxin","ValueMeaning":{"publicId":"3951359","version":"1","preferredName":"in vivo Immunotoxin","longName":"3951359","preferredDefinition":"Located or occurring in the body; the opposite of in vitro (located or occurring outside the body).: Agents comprised of various toxic molecules (Radioactive Isotopes and Bacterial or Plant Toxins) conjugated with specific immune substances (Immunoglobulins, Monoclonal Antibodies, and Antigens)that targets affected cells allowing incorporation of the toxin into the cells.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"In Vivo","conceptCode":"C15744","definition":"Located or occurring in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunotoxin","conceptCode":"C575","definition":"Agents comprised of various toxic molecules (Radioactive Isotopes and Bacterial or Plant Toxins) conjugated with specific immune substances (Immunoglobulins, Monoclonal Antibodies, and Antigens) that targets affected cells allowing incorporation of the toxin into the cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAE91AA1-BDA3-7D56-E040-BB89AD4361DC","latestVersionIndicator":"Yes","beginDate":"2013-11-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAE91AA1-BDBC-7D56-E040-BB89AD4361DC","beginDate":"2013-11-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"ONEDATA","dateModified":"2013-11-11","deletedIndicator":"No"},{"value":"In vivo monoclonal antibody","valueDescription":"in vivo Monoclonal Antibody","ValueMeaning":{"publicId":"2775671","version":"1","preferredName":"in vivo Monoclonal Antibody","longName":"2775671","preferredDefinition":"Located or occurring in the body; the opposite of in vitro (located or occurring outside the body).: An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"In Vivo","conceptCode":"C15744","definition":"Located or occurring in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FB5BE0-0193-7379-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAE91AA1-BDC6-7D56-E040-BB89AD4361DC","beginDate":"2013-11-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"ONEDATA","dateModified":"2013-11-11","deletedIndicator":"No"},{"value":"Cyclophosphamide (Cytoxan)","valueDescription":"Cyclophosphamide","ValueMeaning":{"publicId":"2757911","version":"1","preferredName":"Cyclophosphamide","longName":"2757911","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F5148FD-83F7-3F65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"KUMMEROA","dateModified":"2022-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAEAC187-113E-A8B2-E040-BB89AD43053B","beginDate":"2013-11-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"ONEDATA","dateModified":"2013-11-11","deletedIndicator":"No"},{"value":"Cyclosporine (CSA, Neoral, Sandimmune)","valueDescription":"Cyclosporine","ValueMeaning":{"publicId":"2567427","version":"1","preferredName":"Cyclosporine","longName":"2567427","preferredDefinition":"11-residue cyclic peptide produced by certain fungi which has antifungal and T cell specific immunosuppressive properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclosporine","conceptCode":"C406","definition":"A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D470-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC1535C5-6E74-86C9-E040-BB89AD4360E5","beginDate":"2008-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-26","modifiedBy":"ONEDATA","dateModified":"2013-11-26","deletedIndicator":"No"},{"value":"Extra-corporeal photopheresis (ECP)","valueDescription":"Extracorporeal Photopheresis","ValueMeaning":{"publicId":"2777671","version":"1","preferredName":"Extracorporeal Photopheresis","longName":"2777671","preferredDefinition":"A procedure in which blood is removed from the body and treated with ultraviolet light and drugs that become active when exposed to light. The blood is then returned to the body. It is being studied in the treatment of some blood and bone marrow diseases and graft-vs-host disease (GVHD).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extracorporeal Photopheresis","conceptCode":"C62729","definition":"A procedure which combines apheresis and photodynamic therapy, resulting in blood being treated with a photosensitizing agent and subsequently irradiated with specified wavelengths of light to achieve an effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"554B1B7C-0FF8-6EED-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC1535C5-6E88-86C9-E040-BB89AD4360E5","beginDate":"2008-08-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-26","modifiedBy":"ONEDATA","dateModified":"2013-11-26","deletedIndicator":"No"},{"value":"Mycophenolate mofetil (MMF) (Cellcept)","valueDescription":"Mycophenolate","ValueMeaning":{"publicId":"2578310","version":"1","preferredName":"Mycophenolate","longName":"2578310","preferredDefinition":"The morpholinoethyl ester of mycophenolic acid (MPA).  As an immunosuppressive agent in vivo, the active metabolite mycophenolate reversibly inhibits inosine 5'-monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanine nucleotides, thereby retarding T-cell and B-cell proliferation.  MPA displays high lymphocyte specificity and cytotoxicity because lymphocyte metabolism is highly dependent on both salvage and de novo synthesis of guanine nucleotides. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycophenolate","conceptCode":"C29272","definition":"The morpholinoethyl ester of mycophenolic acid (MPA).  As an immunosuppressive agent in vivo, the active metabolite mycophenolate reversibly inhibits inosine 5'-monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanine nucleotides, thereby retarding T-cell and B-cell proliferation.  MPA displays high lymphocyte specificity and cytotoxicity because lymphocyte metabolism is highly dependent on both salvage and de novo synthesis of guanine nucleotides. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EC1535C5-6E9C-86C9-E040-BB89AD4360E5","beginDate":"2008-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-26","modifiedBy":"ONEDATA","dateModified":"2013-11-26","deletedIndicator":"No"},{"value":"Ruxolitinib","valueDescription":"Ruxolitinib","ValueMeaning":{"publicId":"5125106","version":"1","preferredName":"Ruxolitinib","longName":"5125106","preferredDefinition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ruxolitinib","conceptCode":"C77888","definition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A87E-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75B05ACA-7151-3C89-E053-F662850AC24F","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","deletedIndicator":"No"},{"value":"Anti CD 25","valueDescription":"Daclizumab","ValueMeaning":{"publicId":"5127373","version":"1","preferredName":"Daclizumab","longName":"5127373","preferredDefinition":"A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daclizumab","conceptCode":"C1569","definition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F951-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75B05ACA-715B-3C89-E053-F662850AC24F","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","deletedIndicator":"No"},{"value":"Tacrolimus","valueDescription":"Tacrolimus","ValueMeaning":{"publicId":"3305284","version":"1","preferredName":"Tacrolimus","longName":"3305284","preferredDefinition":"A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tacrolimus","conceptCode":"C1311","definition":"A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-7062-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75AF6CD8-4915-4E44-E053-F662850AD113","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","deletedIndicator":"No"},{"value":"Tocilizumab","valueDescription":"Tocilizumab","ValueMeaning":{"publicId":"4618052","version":"1","preferredName":"Tocilizumab","longName":"4618052","preferredDefinition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. Il-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders and certain types of cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tocilizumab","conceptCode":"C84217","definition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0953B289-65BB-6299-E050-BB89AD4328C8","latestVersionIndicator":"Yes","beginDate":"2014-12-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75AF6CD8-491F-4E44-E053-F662850AD113","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","deletedIndicator":"No"},{"value":"Maraviroc","valueDescription":"Maraviroc","ValueMeaning":{"publicId":"6429534","version":"1","preferredName":"Maraviroc","longName":"6429534","preferredDefinition":"A C-C Chemokine Receptor Type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV). Maraviroc inhibits HIV-1 entry via CCR5 coreceptor interaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maraviroc","conceptCode":"C73144","definition":"A C-C Chemokine Receptor Type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV). Maraviroc inhibits HIV-1 entry via CCR5 coreceptor interaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AF6CD8-492C-4E44-E053-F662850AD113","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75AF6CD8-4945-4E44-E053-F662850AD113","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","deletedIndicator":"No"},{"value":"Bortezomib","valueDescription":"Bortezomib","ValueMeaning":{"publicId":"5127395","version":"1","preferredName":"Bortezomib","longName":"5127395","preferredDefinition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FA1B-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75AF6CD8-494F-4E44-E053-F662850AD113","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","deletedIndicator":"No"},{"value":"Abatacept","valueDescription":"Abatacept","ValueMeaning":{"publicId":"6429536","version":"1","preferredName":"Abatacept","longName":"6429536","preferredDefinition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abatacept","conceptCode":"C28898","definition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AF6CD8-495C-4E44-E053-F662850AD113","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75AF6CD8-4975-4E44-E053-F662850AD113","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","deletedIndicator":"No"},{"value":"Filgotinib","valueDescription":"Filgotinib","ValueMeaning":{"publicId":"6436748","version":"1","preferredName":"Filgotinib","longName":"6436748","preferredDefinition":"An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. As JAK1 mediates signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation and activation of certain immune cells. JAK1 plays a key role in the signaling and activity of many cytokines and growth factors and is often dysregulated in a variety of autoimmune and inflammatory diseases, as well as some malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgotinib","conceptCode":"C155799","definition":"An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. As JAK1 mediates signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation and activation of certain immune cells. JAK1 plays a key role in the signaling and activity of many cytokines and growth factors and is often dysregulated in a variety of autoimmune and inflammatory diseases, as well as some malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7650AE86-C2FC-752F-E053-F662850A5971","latestVersionIndicator":"Yes","beginDate":"2018-09-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-20","modifiedBy":"ONEDATA","dateModified":"2018-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7650AE86-C315-752F-E053-F662850A5971","beginDate":"2018-09-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-20","modifiedBy":"ONEDATA","dateModified":"2018-09-20","deletedIndicator":"No"},{"value":"Ex-vivo T-cell depletion","valueDescription":"Ex-vivo T-Cell Depletion","ValueMeaning":{"publicId":"6436749","version":"1","preferredName":"Ex-vivo T-Cell Depletion","longName":"6436749","preferredDefinition":"Treatment that reduces or removes T cells from a graft before administration to the recipient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ex-vivo T-Cell Depletion","conceptCode":"C155795","definition":"Treatment that reduces or removes T cells from a graft before administration to the recipient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7650AE86-C321-752F-E053-F662850A5971","latestVersionIndicator":"Yes","beginDate":"2018-09-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-20","modifiedBy":"ONEDATA","dateModified":"2018-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7650AE86-C33A-752F-E053-F662850A5971","beginDate":"2018-09-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-20","modifiedBy":"ONEDATA","dateModified":"2018-09-20","deletedIndicator":"No"},{"value":"CD34 enriched","valueDescription":"CD34 Antigen Positive Selection","ValueMeaning":{"publicId":"3852197","version":"1","preferredName":"CD34 Antigen Positive Selection","longName":"3852197","preferredDefinition":"A protein found on the surface of some bone marrow and blood cells.: The separation of specific cells or cell populations from a heterogeneous mixture. Specifically it refers to the selective retention of a population of desired cells through recognition of cells bearing the specified characteristics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Progenitor Cell Antigen CD34","conceptCode":"C17280","definition":"Hematopoietic progenitor cell antigen CD34 (385 aa, ~41 kDa) is encoded by the human CD34 gene. This protein plays a role in cell-cell adhesion and may have a role in leukocyte migration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Positive Selection","conceptCode":"C71257","definition":"The selective retention of a population of desired cells through recognition of cells bearing specific characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E387D3D6-6CCC-7024-E040-BB89AD433EAF","latestVersionIndicator":"Yes","beginDate":"2013-08-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-08-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7D4E3318-94C6-76D8-E053-F662850ADEF4","beginDate":"2018-12-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-12-18","modifiedBy":"ONEDATA","dateModified":"2018-12-18","deletedIndicator":"No"},{"value":"None of the above","valueDescription":"None of the Above","ValueMeaning":{"publicId":"5913672","version":"1","preferredName":"None of the Above","longName":"5913672","preferredDefinition":"None of the choices above are suitable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None of the Above","conceptCode":"C133298","definition":"None of the choices above are suitable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5499ACEF-10D1-1155-E053-F662850A3955","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-07-18","modifiedBy":"KUMMEROA","dateModified":"2022-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8424C52E-079C-72E1-E053-F662850AB1DA","beginDate":"2019-03-15","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-15","modifiedBy":"ONEDATA","dateModified":"2019-03-15","deletedIndicator":"No"},{"value":"Calcineurin-inhibitor and methotrexate or mycophenolate mofetil +/- antithymocyte globulin","valueDescription":"Calcineurin inhibitor And Methotrexate Or Mycophenolate Mofetil With Or Without Anti-Thymocyte Globulin Graft Versus Host Disease Prophylaxis/Therapy","ValueMeaning":{"publicId":"6679184","version":"1","preferredName":"Calcineurin inhibitor And Methotrexate Or Mycophenolate Mofetil With Or Without Anti-Thymocyte Globulin Graft Versus Host Disease Prophylaxis/Therapy","longName":"6679184","preferredDefinition":"Any agent that inhibits calcineurin (protein phosphatase 3; PPP3), a serine/threonine protein phosphatase dependent on calcium and calmodulin, with immunosuppressant activity. Inhibition of calcineurin prevents dephosphorylation of the transcription factor nuclear factor of activated T-cells, cytoplasmic (NFATc), which prevents its translocation to the nucleus and the subsequent induction of the expression of interleukin-2 (IL-2). This prevents IL-2-mediated proliferation and activation of T-cells, and T-lymphocyte-mediated immune responses.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04): Used to indicate the presence of something or someone.: An ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcineurin Inhibitor","conceptCode":"C146638","definition":"Any agent that inhibits calcineurin (protein phosphatase 3; PPP3), a serine/threonine protein phosphatase dependent on calcium and calmodulin, with immunosuppressant activity. Inhibition of calcineurin prevents dephosphorylation of the transcription factor nuclear factor of activated T-cells, cytoplasmic (NFATc), which prevents its translocation to the nucleus and the subsequent induction of the expression of interleukin-2 (IL-2). This prevents IL-2-mediated proliferation and activation of T-cells, and T-lymphocyte-mediated immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Mycophenolate Mofetil","conceptCode":"C1468","definition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Graft Versus Host Disease Prophylaxis/Therapy","conceptCode":"C15448","definition":"Therapy to prevent or treat graft vs host disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848D3D52-DB5B-096B-E053-F662850A2C17","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848D3D52-DB74-096B-E053-F662850A2C17","beginDate":"2019-03-15","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"Calcineurin-inhibitor and sirolimus","valueDescription":"Calcineurin inhibitor And Sirolimus Graft Versus Host Disease Prophylaxis/Therapy","ValueMeaning":{"publicId":"6679185","version":"1","preferredName":"Calcineurin inhibitor And Sirolimus Graft Versus Host Disease Prophylaxis/Therapy","longName":"6679185","preferredDefinition":"Any agent that inhibits calcineurin (protein phosphatase 3; PPP3), a serine/threonine protein phosphatase dependent on calcium and calmodulin, with immunosuppressant activity. Inhibition of calcineurin prevents dephosphorylation of the transcription factor nuclear factor of activated T-cells, cytoplasmic (NFATc), which prevents its translocation to the nucleus and the subsequent induction of the expression of interleukin-2 (IL-2). This prevents IL-2-mediated proliferation and activation of T-cells, and T-lymphocyte-mediated immune responses.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04): Therapy to prevent or treat graft vs host disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcineurin Inhibitor","conceptCode":"C146638","definition":"Any agent that inhibits calcineurin (protein phosphatase 3; PPP3), a serine/threonine protein phosphatase dependent on calcium and calmodulin, with immunosuppressant activity. Inhibition of calcineurin prevents dephosphorylation of the transcription factor nuclear factor of activated T-cells, cytoplasmic (NFATc), which prevents its translocation to the nucleus and the subsequent induction of the expression of interleukin-2 (IL-2). This prevents IL-2-mediated proliferation and activation of T-cells, and T-lymphocyte-mediated immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Sirolimus","conceptCode":"C1212","definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Graft Versus Host Disease Prophylaxis/Therapy","conceptCode":"C15448","definition":"Therapy to prevent or treat graft vs host disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848D3D52-DB83-096B-E053-F662850A2C17","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848D3D52-DB9C-096B-E053-F662850A2C17","beginDate":"2019-03-15","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"Post-transplant cyclophosphamide +/- others","valueDescription":"Post Transplantation Cyclophosphamide With Or Without Other Graft Versus Host Disease Prophylaxis/Therapy","ValueMeaning":{"publicId":"6679186","version":"1","preferredName":"Post Transplantation Cyclophosphamide With Or Without Other Graft Versus Host Disease Prophylaxis/Therapy","longName":"6679186","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.: Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.: A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.: Used to indicate the presence of something or someone.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Used to indicate the absence or lack of something or someone.: Different than the one(s) previously specified or mentioned.: Therapy to prevent or treat graft vs host disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Graft Versus Host Disease Prophylaxis/Therapy","conceptCode":"C15448","definition":"Therapy to prevent or treat graft vs host disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848D3D52-DBAF-096B-E053-F662850A2C17","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"848D3D52-DBC8-096B-E053-F662850A2C17","beginDate":"2019-03-15","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","deletedIndicator":"No"},{"value":"Other in vivo monoclonal antibody","valueDescription":"Other in vivo Monoclonal Antibody","ValueMeaning":{"publicId":"7613933","version":"1","preferredName":"Other in vivo Monoclonal Antibody","longName":"7613933","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Located or occurring in the body.: An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"In Vivo","conceptCode":"C15744","definition":"Located or occurring in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE4C0526-E2A8-3F43-E053-4EBD850A7B1B","latestVersionIndicator":"Yes","beginDate":"2021-03-24","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-24","modifiedBy":"ONEDATA","dateModified":"2021-03-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BFC85BFE-AB09-727E-E053-4EBD850A34E4","beginDate":"2021-04-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-04-12","modifiedBy":"ONEDATA","dateModified":"2021-04-12","deletedIndicator":"No"},{"value":"Alemtuzumab","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BFC85BFE-AB13-727E-E053-4EBD850A34E4","beginDate":"2021-04-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-04-12","modifiedBy":"ONEDATA","dateModified":"2021-04-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2775668","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention Type","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.:An attempt to prevent disease.:Type; a subdivision of a particular kind of thing.","longName":"C3063:C15843:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graft Versus Host Disease","conceptCode":"C3063","definition":"A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FB5BE0-011E-7379-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"ONEDATA","dateModified":"2008-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FB5BE0-012F-7379-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"MALUMK","dateModified":"2021-04-12","changeDescription":". Added PVs for 2400r6. AK 12/18/18 . Added PVs for 2534. 03/15/2019 KMM. PVs added for 2100r7. 04/12/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964924","version":"1","longName":"2400r1: Pre-TED","context":"NHLBI"}]}],"AlternateNames":[{"name":"PreTed_GP_gvhd_prev_interv_typ","type":"NMDP_FN","context":"NHLBI"},{"name":"HPST_AGHD_gvhd_prophy_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the type of GVHD pro","type":"Preferred Question Text","description":"What was the type of GVHD prophylaxis?","url":null,"context":"NHLBI"},{"name":"Specify drugs / intervention","type":"Alternate Question Text","description":"Specify drugs / intervention","url":null,"context":"NHLBI"},{"name":"Specify the recipient's GVHD prophylaxis","type":"Alternate Question Text","description":"Specify the recipient's GVHD prophylaxis","url":null,"context":"NHLBI"},{"name":"Specify the recipient's GVHD prophylaxis","type":"Application Standard Question Text","description":"Specify the recipient's GVHD prophylaxis","url":null,"context":"NHLBI"},{"name":"Select specific therapy used after the start of the preparative regimen to prevent acute GVHD","type":"Alternate Question Text","description":"Select specific therapy used after the start of the preparative regimen to prevent acute GVHD","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5549E666-3166-6868-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-25","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"MALUMK","dateModified":"2021-10-04","changeDescription":". System generated def displayed as alt def. AK 10/16/14 . Added AQT. 03/15/2019 KMM. AQT added for 2100r7. 04/12/2021 KMM. ALT name added for 2100r7. 10/04/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}